美国 · SEC FORM 4
Vaxcyte, Inc.
PCVX · Nasdaq · CIK 0001649094 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
78 同一窗口内观察到的 Form 4 交易行
42 sales · 36 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2020-06-16 · BONDERMAN DAVID; COULTER JAMES G; TPG Group Holdings (SBS) Advisors, Inc..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 17,290,712
- 上期报告
- 16,132,520
- 日均成交量
- 1,517,422
- 回补天数
- 11.4
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2020-06-16 | EMSTER KURT VON | 买入 (P) | Common Stock, $0.001 par value per share | 12,500 | USD 16.00 | USD 200,000 | SEC 申报 ↗ |
| 2020-06-16 | BONDERMAN DAVID; COULTER JAMES G; TPG Group Holdings (SBS) Advisors, Inc. | 买入 (P) | Common Stock | 937,500 | USD 16.00 | USD 15,000,000 | SEC 申报 ↗ |
| 2020-06-16 | Hopfner Robert Lorne | 买入 (P) | Common Stock | 93,000 | USD 16.00 | USD 1,488,000 | SEC 申报 ↗ |
| 2020-06-16 | Heron Patrick J | 买入 (P) | Common Stock | 250,000 | USD 16.00 | USD 4,000,000 | SEC 申报 ↗ |
Form 4 申报证据
118 transaction lines in the latest 365-day window; 929 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Wassil Jim | 卖出 (S) | Common Stock | 18,000 | USD 86.74 | USD 1,561,320 | SEC 申报 ↗ |
| 2026-10-05 | Wassil Jim | 期权行权/转换 (M) | Common Stock | 18,000 | USD 5.35 | USD 96,300 | SEC 申报 ↗ |
| 2026-10-05 | Cowan Elvia | 卖出 (S) | Common Stock | 19,000 | USD 86.74 | USD 1,648,060 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-10-05 | Wassil Jim | 卖出 (S) | Common Stock | 18,000 | USD 86.74 | USD 1,561,320 | SEC 申报 ↗ |
| 2026-10-05 | Wassil Jim | 期权行权/转换 (M) | Common Stock | 18,000 | USD 5.35 | USD 96,300 | SEC 申报 ↗ |
| 2026-10-05 | Cowan Elvia | 卖出 (S) | Common Stock | 19,000 | USD 86.74 | USD 1,648,060 | SEC 申报 ↗ |
| 2026-10-05 | Cowan Elvia | 期权行权/转换 (M) | Common Stock | 19,000 | USD 25.92 | USD 492,480 | SEC 申报 ↗ |
| 2026-10-01 | Wassil Jim | 卖出 (S) | Common Stock | 2,250 | USD 56.67 | USD 127,513 | SEC 申报 ↗ |
| 2026-10-01 | Wassil Jim | 期权行权/转换 (M) | Common Stock | 2,250 | USD 5.35 | USD 12,038 | SEC 申报 ↗ |
| 2026-09-09 | Wassil Jim | 卖出 (S) | Common Stock | 1,334 | USD 59.52 | USD 79,400 | SEC 申报 ↗ |
| 2026-09-08 | Wassil Jim | 代扣税 (F) | Common Stock | 5,459 | USD 60.36 | USD 329,505 | SEC 申报 ↗ |
| 2026-09-08 | PICKERING GRANT | 代扣税 (F) | Common Stock | 17,056 | USD 60.36 | USD 1,029,500 | SEC 申报 ↗ |
| 2026-09-08 | GUGGENHIME ANDREW | 代扣税 (F) | Common Stock | 7,155 | USD 60.36 | USD 431,876 | SEC 申报 ↗ |
| 2026-09-08 | Dhaliwal Harpreet S. | 代扣税 (F) | Common Stock | 7,651 | USD 60.36 | USD 461,814 | SEC 申报 ↗ |
| 2026-09-08 | Cowan Elvia | 代扣税 (F) | Common Stock | 1,327 | USD 60.36 | USD 80,098 | SEC 申报 ↗ |
| 2026-09-04 | Wassil Jim | 卖出 (S) | Common Stock | 1,381 | USD 61.16 | USD 84,462 | SEC 申报 ↗ |
| 2026-09-04 | Jodar Luis | 奖励/授予 (A) | Common Stock | 52,632 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-09-02 | Wassil Jim | 代扣税 (F) | Common Stock | 1,432 | USD 61.58 | USD 88,183 | SEC 申报 ↗ |
| 2026-09-02 | PICKERING GRANT | 代扣税 (F) | Common Stock | 3,427 | USD 61.58 | USD 211,035 | SEC 申报 ↗ |
| 2026-09-02 | GUGGENHIME ANDREW | 代扣税 (F) | Common Stock | 1,432 | USD 61.58 | USD 88,183 | SEC 申报 ↗ |
| 2026-09-02 | Dhaliwal Harpreet S. | 代扣税 (F) | Common Stock | 659 | USD 61.58 | USD 40,581 | SEC 申报 ↗ |
| 2026-09-02 | Cowan Elvia | 代扣税 (F) | Common Stock | 326 | USD 61.58 | USD 20,075 | SEC 申报 ↗ |
| 2026-09-01 | Wassil Jim | 卖出 (S) | Common Stock | 3,477 | USD 61.08 | USD 212,360 | SEC 申报 ↗ |
| 2026-09-01 | Wassil Jim | 期权行权/转换 (M) | Common Stock | 2,250 | USD 5.35 | USD 12,038 | SEC 申报 ↗ |
| 2026-08-31 | Wassil Jim | 代扣税 (F) | Common Stock | 1,273 | USD 60.74 | USD 77,322 | SEC 申报 ↗ |
| 2026-08-31 | PICKERING GRANT | 代扣税 (F) | Common Stock | 2,862 | USD 60.74 | USD 173,838 | SEC 申报 ↗ |
| 2026-08-31 | GUGGENHIME ANDREW | 代扣税 (F) | Common Stock | 1,273 | USD 60.74 | USD 77,322 | SEC 申报 ↗ |
| 2026-08-31 | Dhaliwal Harpreet S. | 代扣税 (F) | Common Stock | 361 | USD 60.74 | USD 21,927 | SEC 申报 ↗ |
| 2026-08-31 | Cowan Elvia | 代扣税 (F) | Common Stock | 243 | USD 60.74 | USD 14,760 | SEC 申报 ↗ |
| 2026-08-05 | Dhaliwal Harpreet S. | 卖出 (S) | Common Stock | 17,000 | USD 55.00 | USD 935,000 | SEC 申报 ↗ |
| 2026-08-05 | Dhaliwal Harpreet S. | 期权行权/转换 (M) | Common Stock | 17,000 | USD 24.79 | USD 421,430 | SEC 申报 ↗ |
| 2026-08-03 | Wassil Jim | 卖出 (S) | Common Stock | 2,250 | USD 53.86 | USD 121,195 | SEC 申报 ↗ |
| 2026-08-03 | Wassil Jim | 期权行权/转换 (M) | Common Stock | 2,250 | USD 5.35 | USD 12,038 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | PCVX |
| CIK | 0001649094 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2836 Biological Products, (No Diagnostic Substances) |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 929 transaction lines from 2020-06-16 to 2026-10-05 4 P purchase lines · 554 S sale lines · 371 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.